156 related articles for article (PubMed ID: 27748803)
1. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
Xie Q; Su J; Jiao B; Shen L; Ma L; Qu X; Yu C; Jiang X; Xu Y; Sun L
Int J Oncol; 2016 Dec; 49(6):2507-2519. PubMed ID: 27748803
[TBL] [Abstract][Full Text] [Related]
2. Nutrient Starvation Sensitizes Human Ovarian Cancer SKOV3 Cells to BH3 Mimetic via Modulation of Mitochondrial Dynamics.
Wang S; Mao Y; Xi S; Wang X; Sun L
Anat Rec (Hoboken); 2017 Feb; 300(2):326-339. PubMed ID: 27486855
[TBL] [Abstract][Full Text] [Related]
3. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
4. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
5. ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics.
Fan Z; Yu H; Cui N; Kong X; Liu X; Chang Y; Wu Y; Sun L; Wang G
Exp Cell Res; 2015 Jul; 335(1):68-81. PubMed ID: 25936772
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
7. Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis.
Xu Y; Wang C; Su J; Xie Q; Ma L; Zeng L; Yu Y; Liu S; Li S; Li Z; Sun L
Oncol Rep; 2015 Dec; 34(6):3051-60. PubMed ID: 26398138
[TBL] [Abstract][Full Text] [Related]
8. The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin.
Geserick P; Wang J; Feoktistova M; Leverkus M
Cell Death Dis; 2014 Sep; 5(9):e1412. PubMed ID: 25210795
[TBL] [Abstract][Full Text] [Related]
9. ABT-737 sensitizes curcumin-induced anti-melanoma cell activity through facilitating mPTP death pathway.
Yu T; Chen C; Sun Y; Sun H; Li TH; Meng J; Shi X
Biochem Biophys Res Commun; 2015 Aug; 464(1):286-91. PubMed ID: 26116776
[TBL] [Abstract][Full Text] [Related]
10. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
[TBL] [Abstract][Full Text] [Related]
11. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
[TBL] [Abstract][Full Text] [Related]
12. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.
Salm F; Cwiek P; Ghosal A; Lucia Buccarello A; Largey F; Wotzkow C; Höland K; Styp-Rekowska B; Djonov V; Zlobec I; Bodmer N; Gross N; Westermann F; Schäfer SC; Arcaro A
Oncogene; 2013 Aug; 32(34):3944-53. PubMed ID: 23027129
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.
Hadjidaniel MD; Reynolds CP
Mol Cancer Ther; 2010 Dec; 9(12):3164-74. PubMed ID: 21159604
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
15. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
16. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
17. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
18. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
[TBL] [Abstract][Full Text] [Related]
19. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
20. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
